InvestSMART

Vitrafy Life Sciences Limited (ASX:VFY)

ALERT: Price-sensitive ASX Announcement for VFY
Current share price for VFY : $3.200 -0.6 (-15.79%)+
Announcement
Release
12 Jun 2026 9:33AM
Price at Release
$3.800
Full Release
download
Summary
Vitrafy Life Sciences Limited is raising $30 million through a non-underwritten institutional placement at $2.60 per share to fund the expansion of its cryopreservation device fleet and boost US operations. A concurrent share purchase plan aims to raise an additional $2 million. The raised funds will support manufacturing, sales, and marketing efforts to meet the anticipated demand for their devices. Vitrafy's strategy involves entering the US market, focusing on applications across animal reproduction, blood, cell, and gene therapies. The company is navigating various risks including commercialisation hurdles and the need for additional funding.
Key Points
  • Vitrafy is conducting a non-underwritten institutional placement to raise approximately $30 million.
  • The placement price is $2.60 per share, representing a 31.6% discount to the last close price.
  • Funds raised will be used for manufacturing, US operations, and sales and marketing activities.
  • Vitrafy plans to scale its operational cryopreservation device fleet in the U.S.
  • The company will also launch a share purchase plan to raise an additional $2 million.
  • Vitrafy faces risks such as commercialisation challenges and funding needs.
  • The company has limited operating history and relies on key relationships.
  • Vitrafy is developing a cryopreservation technology for various applications.
  • The company aims to expand into U.S. markets with new devices.
  • Vitrafy aims to address supply shortages in cryopreserved blood products.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.